Novogen Cash Reserves $25.4M, Phenoxodiol Receives US FDA Clearance for Phase III Human Trial Pharmaceutical company Novogen Limited, has ended the 2005/06 financial year with solid cash reserves and US Food and Drug Administration (FDA) clearance for the final phase of human clinical testing of its lead anti-cancer drug, phenoxodiol. Revenue for the year ended 30 June, 2006, was $13.9 million, a 3.2 percent improvement over the previous corresponding period of $13.4 million [more...]
